Xperiome™ Labs

Learn how we turn patient engagement into insight using the Xperiome platform.

Research

Learn about the research studies we conduct with commercial and academic partners, and the clinical trials we support for pharmaceutical sponsors.

Active
A Raremark study: What do you think about your myasthenia gravis treatment(s)?
This study aims to learn what people with myasthenia gravis actually think about taking the medication(s) eculizumab (Soliris), neostigmine (Bloxiverz), and/or pyridostigmine (Mestinon, Regonol). This is not like other studies that may only focus on following doctors’ orders.
Completed
Xperiome study: What do you think about your sickle cell treatment(s)?
This study aims to learn what people with sickle cell actually think about taking the newer sickle cell medications – Adakveo (crizanlizumab), Endari (L-glutamine), and Oxbryta (voxelotor) – and see how they compare with the older drug, hydroxyurea. This is not like other studies that may only focus on following doctors’ orders.
Completed
Anti-AChR antibody-positive generalized myasthenia gravis clinical research study
This placebo-controlled Phase 3 study is testing an investigational medicine called ravulizumab-cwvz, also known in this study as ALXN1210, on adults with anti-AChR antibody-positive, generalized myasthenia gravis (gMG).
Completed
Generalized myasthenia gravis (gMG) clinical research study (ASCEND-MG)
ASCEND-MG is a randomized, placebo-controlled study, testing an investigational medicine called RVT-1401 on adults with generalized myasthenia gravis (gMG).
View all research

Case studies

Discover how we’re making our mark in research and accelerating the development and reach of new treatments.

Case study
Patient preferences for injectable drug-delivery options

A pharmaceutical company commissioned Xperiome to survey our sickle cell community to understand how people living with the condition handle their pain crises and hospital visits, and how they would feel about different ways to take or receive a new injectable medication.

Read more
Case study
Longitudinal, real-world data to support US FDA submission

A specialist pharmaceutical company commissioned Xperiome to recruit a group of people living with pouchitis, a rare gastrointestinal condition, and to track how it affects their lives over a six-month period.

Read more
Case study
Phase I study to assess safety and tolerability of investigative medication in pediatric patients with Sanfilippo syndrome (MPS IIIA)

A specialty healthcare company developing treatments for rare diseases sought Xperoime’s support for an early-stage pediatric trial program testing an investigational medicine in Sanfilippo syndrome.

Read more
Case study
Phase II study to evaluate safety and efficacy of investigative medication in adults with generalized MG

A clinical-stage biopharmaceutical company developing treatments for autoimmune diseases brought in Xperiome to boost recruitment to a Phase II study of an experimental drug for generalized myasthenia gravis (MG); a super-hot area for clinical research experiencing high competition for eligible patients.

Read more
View all case studies

Sign up for updates

If you’re an industry professional and would like to subscribe to updates from our research team, including our research projects and our Rare Opinion blog, fill in your details below and we’ll add you to our mailing list.

Visit our Virtual Venue to find out how Xperiome can help you unlock deep insights into rare patient experience.

Go to Virtual Venue